Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Association between Apolipoprotein E Polymorphism and Response to Statins in Group of Hyperlipidemic Patients

Author(s): Rasha Jabr, Munir Gharaibeh, Ayman A. Zayed and Malek Zihlif*

Volume 21, Issue 4, 2021

Published on: 05 July, 2020

Page: [720 - 725] Pages: 6

DOI: 10.2174/1871530320666200705211656

Price: $65

Abstract

Background and Objective: APOE has an important role in lipids metabolism, and in the variability in low density lipoprotein (LDL) response to statins treatment between individuals. In this study, we aim to investigate the association between APOE polymorphism and response to statins in Jordanian hyperlipidemic patients at the diabetic clinic of Jordan University Hospital.

Methods: One hundred and fifty two Jordanian Hyperlipidemic patients (52 males and 100 females) aged between 35-75 years were enrolled in this study. This study was approved by the Institutional Review Board (IRB) of Jordan University Hospital. The genotypes of the patients were identified by polymerase chain reaction followed by restriction fragment length polymorphism assay method (PCRRFLP).

Results and Conclusion: The study showed that there is an association between APOE polymorphism and response to statin therapy. Patients who were APOE ε4 carriers had lower response to statins compared to ε3 and ε2 carriers (p=0.002). In addition, we found that there was no significant association between APOE polymorphism and LDL baseline (p=0.214). No significant differences were found in APOE genotypes distribution between males and females (p=0.06). No significant association was found between age and APOE genotypes (p=0.347). A genotype screening test for dyslipidemic Jordanian patients is recommended to choose the appropriate treatment decisions, dosage, and to recognize the potential side effects of statin therapy.

Keywords: Polymorphism, apolipoprotein, APOE, statins, Jordanian, hyperlipidemic patients.

« Previous Next »
Graphical Abstract

[1]
Azar, S.T.; Hantash, H.A.; Jambart, S.; El-Zaheri, M.M.; Rachoin, R.; Chalfoun, A.; Lahoud, L.; Okkeh, O.; Bramlage, P.; Brudi, P.; Ambegaonkar, B.M. Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the dyslipidemia international study. Vasc. Health Risk Manag., 2014, 10, 225-235.
[PMID: 24872710]
[2]
Clark, M. A.; Finkel, R.; Rey, J. A.; Whalen, K. Lippincott's Illustrated Reviews., 2012.
[3]
Superko, H.R.; Momary, K.M.; Li, Y. Statins personalized. Med. Clin. North Am., 2012, 96(1), 123-139.
[http://dx.doi.org/10.1016/j.mcna.2011.11.004] [PMID: 22391257]
[4]
Baptista, R.; Rebelo, M.; Decq-Mota, J.; Dias, P.; Monteiro, P.; Providência, L.A.; Silva, J.M. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis., 2011, 10, 48.
[http://dx.doi.org/10.1186/1476-511X-10-48] [PMID: 21450082]
[5]
Tavintharan, S.; Lim, S.C.; Chan, Y.H.; Sum, C.F. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2007, 9(1), 81-86.
[http://dx.doi.org/10.1111/j.1463-1326.2006.00577.x] [PMID: 17199722]
[6]
Chiodini, B.D.; Franzosi, M.G.; Barlera, S.; Signorini, S.; Lewis, C.M.; D’Orazio, A.; Mocarelli, P.; Nicolis, E.; Marchioli, R.; Tognoni, G.; Investigators, G. GISSI investigators. SIBioC-GISSI Prevenzione group. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J., 2007, 28(16), 1977-1983.
[http://dx.doi.org/10.1093/eurheartj/ehm196] [PMID: 17567623]
[7]
Bazzaz, J.T.; Nazari, M.; Nazem, H.; Amiri, P.; Fakhrzadeh, H.; Heshmat, R.; Abbaszadeh, S.; Amoli, M.M. Apolipoprotein E gene polymorphism and total serum cholesterol level in Iranian population. J. Postgrad. Med., 2010, 56(3), 173-175.
[http://dx.doi.org/10.4103/0022-3859.68629] [PMID: 20739760]
[8]
Eichner, J.E.; Dunn, S.T.; Perveen, G.; Thompson, D.M.; Stewart, K.E.; Stroehla, B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol., 2002, 155(6), 487-495.
[http://dx.doi.org/10.1093/aje/155.6.487] [PMID: 11882522]
[9]
Ballantyne, C.M.; Herd, J.A.; Stein, E.A.; Ferlic, L.L.; Dunn, J.K.; Gotto, A.M., Jr; Marian, A.J. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol., 2000, 36(5), 1572-1578.
[http://dx.doi.org/10.1016/S0735-1097(00)00918-9] [PMID: 11079660]
[10]
Maitland-van der Zee, A.H.; Stricker, B.H.; Klungel, O.H.; Mantel-Teeuwisse, A.K.; Kastelein, J.J.; Hofman, A.; Leufkens, H.G.; van Duijn, C.M.; de Boer, A. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics, 2003, 13(4), 219-223.
[http://dx.doi.org/10.1097/00008571-200304000-00006] [PMID: 12668918]
[11]
Lagos, J.; Zambrano, T.; Rosales, A.; Salazar, L. A 2015APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects. Int. J. Mol. Sci., 2015, 16(4), 7890.
[http://dx.doi.org/10.3390/ijms16047890]
[12]
Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.L.; Braunwald, E.; Sabatine, M.S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009, 119(19), 2553-2560.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.851949]
[13]
Peña, R.; Lahoz, C.; Mostaza, J.M.; Jiménez, J.; Subirats, E.; Pintó, X.; Taboada, M.; López-Pastor, A. Rap study group. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med., 2002, 251(6), 518-525.
[http://dx.doi.org/10.1046/j.1365-2796.2002.00991.x] [PMID: 12028507]
[14]
Zintzaras, E.; Kitsios, G.D.; Triposkiadis, F.; Lau, J.; Raman, G. APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J., 2009, 9(4), 248-257.
[http://dx.doi.org/10.1038/tpj.2009.25] [PMID: 19529002]
[15]
Ojala, J.P.; Helve, E.; Ehnholm, C.; Aalto-Setälä, K.; Kontula, K.K.; Tikkanen, M.J. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J. Intern. Med., 1991, 230(5), 397-405.
[http://dx.doi.org/10.1111/j.1365-2796.1991.tb00464.x] [PMID: 1940775]
[16]
De Knijff, P.; Stalenhoef, A.F.; Mol, M.J.; Gevers Leuven, J.A.; Smit, J.; Erkelens, D.W.; Schouten, J.; Frants, R.R.; Havekes, L.M. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 1990, 83(1), 89-97.
[http://dx.doi.org/10.1016/0021-9150(90)90134-5] [PMID: 2390138]
[17]
Elmadbouh, I.; Elghobashy, Y.; Abd-Allah, E.; Reda, A.; Fathe, A.; Tayel, S.; Abd-Elhakim, T. Relationship of apolipoprotein E polymorphism with lipid profiles in atherosclerotic coronary artery disease. J. Saudi Heart Assoc., 2012, 24(4), 287.
[http://dx.doi.org/10.1016/j.jsha.2012.06.233]
[18]
Gregório, M.L.; Pinhel, M.A.; Sado, C.L.; Longo, G.S.; Oliveira, F.N.; Amorim, G.S.; Nakazone, M.A.; Florim, G.M.; Mazeti, C.M.; Martins, D.P.; Tognola, W.A.; Brandão, A.C.; Júnior, S.P.; de Godoy, M.F.; Souza, D.R. Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson’s disease. BioMed Res. Int., 2013, 2013641515
[http://dx.doi.org/10.1155/2013/641515]] [PMID: 24175296]
[19]
Lin, S.K.; Kao, J.T.; Tsai, S.M.; Tsai, L.Y.; Lin, M.N.; Lai, C.J.; Zhong, W.L. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Taiwan. Ann. Clin. Lab. Sci., 2004, 34(4), 443-448.
[PMID: 15648787]
[20]
Hagberg, J.M.; Ferrell, R.E.; Katzel, L.I.; Dengel, D.R.; Sorkin, J.D.; Goldberg, A.P. Apolipoprotein E genotype and exercise training-induced increases in plasma high-density lipoprotein (HDL)- and HDL2-cholesterol levels in overweight men. Metabolism, 1999, 48(8), 943-945.
[http://dx.doi.org/10.1016/S0026-0495(99)90185-3] [PMID: 10459553]
[21]
Davignon, J.; Gregg, R.E.; Sing, C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis, 1988, 8(1), 1-21.
[http://dx.doi.org/10.1161/01.ATV.8.1.1] [PMID: 3277611]

Rights & Permissions Print Cite
Article Metrics
15
2
© 2024 Bentham Science Publishers | Privacy Policy